Comparing niraparib and bevacizumab for ovarian cancer maintenance therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to compare the progression-free survival of patients with high-grade stage III and IV ovarian carcinoma who have received first-line platinum-based chemotherapy followed by maintenance treatment with either niraparib or bevacizumab. The study will utilize a retrospective, multicenter approach, analyzing data collected from patients' medical records. It focuses on patients without BRCA mutations or high homologous recombination deficiency scores, who are typically treated with these two maintenance therapies. The goal is to determine if there are significant differences in outcomes between the two treatment options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* De novo diagnosis of stage III or IV high-grade epithelial ovarian carcinoma, not candidate for primary tumor reduction surgery.
* De novo diagnosis of high-grade epithelial ovarian carcinoma benefiting from a combination of chemotherapy and maximal cytoreduction surgery
* All patients who have received maintenance treatment after chemotherapy with bevacizumab or niraparib monotherapy.

Exclusion Criteria:

* Disease progression after chemotherapy
* Presence of a BRCA mutation (somatic or germline)
* Positive HRD score

Where it's running

• CHU de Nîmes
  Nîmes, Occitanie, France Recruiting

Study contacts

• Principal investigator: soufyan annakib, M.D.
• Study coordinator: Soufyan Annakib, M.D.
• Email: soufyan.annakib@gmail.com
• Phone: +33466683301

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing Olaparib with or without Bevacizumab for Ovarian Cancer Treatment

  This study is testing if a new cancer treatment called olaparib, alone or with another drug called bevacizumab, can help women with advanced ovarian cancer live longer without their cancer getting worse.

  Recruiting at 682 sites Phase 3 NRG Oncology · Birmingham, Alabama and 708 other locations · NCT06580314

• Treatment for recurrent ovarian cancer with HER2 expression

  This study is testing a new combination of treatments for women with recurrent ovarian cancer that has a specific protein called HER2 to see if it helps them feel better and live longer.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT06420973

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• Bevacizumab for severe HHT-related nosebleeds

  This study tests whether bevacizumab can help people with hereditary hemorrhagic telangiectasia who have severe nosebleeds.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07828015

• Torvutatug samrotecan with or without bevacizumab as maintenance in platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This study tests torvutatug samrotecan, with or without bevacizumab, to see if it helps people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer stay cancer-free longer after their last platinum therapy.

  Recruiting at 3 sites Phase 3 AstraZeneca · Anchorage, Alaska and 123 other locations · NCT07816666

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.